The downstream enzyme farnesyl diphosphate synthase (FDPS) is the target of the nitrogenous bisphosphonates including risedronate (3) and zoledronate (4), which are widely used for treatment of osteoporosis [2]. This evidence concerns the gene FDPS and osteoporosis.